Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Geovax Labs (GOVX)

Geovax Labs (GOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,911
  • Shares Outstanding, K 9,436
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,970 K
  • EBIT $ -24 M
  • EBITDA $ -24 M
  • 60-Month Beta 3.10
  • Price/Sales 2.79
  • Price/Cash Flow N/A
  • Price/Book 2.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.79
  • Number of Estimates 3
  • High Estimate -0.60
  • Low Estimate -1.00
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.75 +50.84%
on 11/04/24
3.88 -31.97%
on 11/12/24
+0.72 (+37.48%)
since 11/01/24
3-Month
1.75 +50.84%
on 11/04/24
4.83 -45.35%
on 09/03/24
-1.99 (-42.99%)
since 08/30/24
52-Week
1.09 +142.15%
on 06/18/24
11.18 -76.39%
on 08/19/24
-3.57 (-57.49%)
since 12/01/23

Most Recent Stories

More News
3 Penny Stocks Ready to Break Out in 2025

Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.

VUZI : 2.66 (+15.15%)
CRDL : 1.5863 (-2.08%)
GOVX : 2.59 (-1.89%)
GeoVax Labs, Inc. CEO David Dodd to Present at NobleCon20 Conference

GeoVax Labs announces CEO David Dodd will present at NobleCon20 on corporate updates and clinical trials.Quiver AI SummaryGeoVax Labs, Inc., a biotechnology company focused on human vaccines and cancer...

GOVX : 2.59 (-1.89%)
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement.

SIGA : 7.16 (-1.65%)
EBS : 10.06 (-0.59%)
GOVX : 2.59 (-1.89%)
CMRX : 0.8600 (-2.27%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

ONCY : 0.9088 (-2.30%)
ONC.TO : 1.30 (-1.52%)
GOVX : 2.59 (-1.89%)
GSK : 34.15 (+0.06%)
AZN : 66.92 (-1.04%)
MRK : 100.82 (-0.81%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

ONCY : 0.9088 (-2.30%)
ONC.TO : 1.30 (-1.52%)
GOVX : 2.59 (-1.89%)
GSK : 34.15 (+0.06%)
AZN : 66.92 (-1.04%)
MRK : 100.82 (-0.81%)
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA,...

GOVX : 2.59 (-1.89%)
GOVXW : 0.1272 (+13.37%)
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and...

GOVXW : 0.1272 (+13.37%)
GOVX : 2.59 (-1.89%)
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...

GOVXW : 0.1272 (+13.37%)
GOVX : 2.59 (-1.89%)
GeoVax to Present at BIO International Convention 2022

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE)...

GOVXW : 0.1272 (+13.37%)
GOVX : 2.59 (-1.89%)
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing...

GOVXW : 0.1272 (+13.37%)
GOVX : 2.59 (-1.89%)

Business Summary

GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.

See More

Key Turning Points

3rd Resistance Point 2.86
2nd Resistance Point 2.81
1st Resistance Point 2.72
Last Price 2.59
1st Support Level 2.59
2nd Support Level 2.54
3rd Support Level 2.45

See More

52-Week High 11.18
Fibonacci 61.8% 7.33
Fibonacci 50% 6.14
Fibonacci 38.2% 4.94
Last Price 2.59
52-Week Low 1.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar